Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × INDUSTRY × dolasetron × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 1 Neoplasms 1 Nausea 1

Interventions

Paclitaxel 394 Carboplatin 345 Docetaxel 325 Gemcitabine 318 Cisplatin 289 Bevacizumab 275 pembrolizumab 272 Nivolumab 203 Pemetrexed 198 Capecitabine 191 Dexamethasone 169 Rituximab 164 Fluorouracil 162 Cyclophosphamide 156 Trastuzumab 154 Oxaliplatin 131 atezolizumab 123 Prednisone 122 Ipilimumab 121 Erlotinib Hydrochloride 119 Cetuximab 119 Irinotecan 111 Doxorubicin 111 Leucovorin 104 Bortezomib 101 Sorafenib 95 Sunitinib 93 Lenalidomide 91 Everolimus 79 Radiotherapy 78

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01636947 2018-09-25

KMEC

Merck Sharp & Dohme LLC

Phase 4 Completed

494 enrolled 14 charts

Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon ⚡